MX2019006107A - Composiciones de arsenico. - Google Patents
Composiciones de arsenico.Info
- Publication number
- MX2019006107A MX2019006107A MX2019006107A MX2019006107A MX2019006107A MX 2019006107 A MX2019006107 A MX 2019006107A MX 2019006107 A MX2019006107 A MX 2019006107A MX 2019006107 A MX2019006107 A MX 2019006107A MX 2019006107 A MX2019006107 A MX 2019006107A
- Authority
- MX
- Mexico
- Prior art keywords
- arsenic trioxide
- arsenic
- compositions
- nahas2o4
- realisation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Detergent Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se postula en la realización de que los problemas con la pobre solubilidad del agua del trióxido de arsénico y la dificultad extrema en disolver trióxido arsénico en cualquiera diferente de una solución muy básica, se podría superar al formar un tetraóxido de diarsénico mucho más soluble, que incluye el compuesto NaHAs2O4, antes de su suministro a un paciente. Se describen composiciones farmacéuticas con tales compuestos y su uso en el tratamiento de cánceres.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016904945A AU2016904945A0 (en) | 2016-12-01 | Arsenic compositions | |
| PCT/AU2017/050807 WO2018098519A1 (en) | 2016-12-01 | 2017-08-02 | Arsenic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019006107A true MX2019006107A (es) | 2019-08-21 |
Family
ID=62240940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006107A MX2019006107A (es) | 2016-12-01 | 2017-08-02 | Composiciones de arsenico. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11241453B2 (es) |
| EP (1) | EP3548044B1 (es) |
| JP (2) | JP7080230B2 (es) |
| KR (1) | KR102487884B1 (es) |
| CN (1) | CN109952105A (es) |
| AU (1) | AU2017368444B9 (es) |
| BR (1) | BR112019007498A2 (es) |
| CA (1) | CA3041357A1 (es) |
| CL (1) | CL2019001422A1 (es) |
| DK (1) | DK3548044T3 (es) |
| ES (1) | ES2964979T3 (es) |
| IL (1) | IL265986B (es) |
| MX (1) | MX2019006107A (es) |
| NZ (1) | NZ752214A (es) |
| PE (1) | PE20191544A1 (es) |
| PL (1) | PL3548044T3 (es) |
| SA (1) | SA519401885B1 (es) |
| SG (1) | SG11201903064SA (es) |
| TW (1) | TWI808060B (es) |
| WO (1) | WO2018098519A1 (es) |
| ZA (1) | ZA201902156B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3490939B1 (en) | 2016-08-01 | 2021-11-03 | Veolia Water Solutions & Technologies Support | Process for removing silica from produced water |
| MX2019006107A (es) * | 2016-12-01 | 2019-08-21 | Eupharma Pty Ltd | Composiciones de arsenico. |
| WO2022180582A1 (en) * | 2021-02-26 | 2022-09-01 | Intas Pharmaceuticals Ltd. | Oral pharmaceutical composition of arsenic trioxide |
| JP2022151442A (ja) * | 2021-03-26 | 2022-10-07 | 均 石井 | 白血病治療薬。 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2080004A (en) * | 1933-05-17 | 1937-05-11 | Frederick E Dearborn | Double salt of copper arsenite and a copper salt of an unsaturated fatty acid and process of making the same |
| US3280046A (en) | 1963-03-27 | 1966-10-18 | Dow Chemical Co | Polyol ether resins and utility |
| AU751932B2 (en) | 1997-10-15 | 2002-08-29 | Polarx Biopharmaceuticals, Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| EP1964557B1 (en) | 1997-11-10 | 2013-01-02 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations |
| CN1471925A (zh) * | 2002-08-02 | 2004-02-04 | 丛繁滋 | 更适于硬质肿瘤直接给药的含砷组合物、制剂及制备方法 |
| US7521071B2 (en) | 2002-10-09 | 2009-04-21 | Versitech Limited | Formulation of oral compositions comprising arsenic trioxide and methods of use thereof |
| EP1721615A1 (en) | 2005-05-09 | 2006-11-15 | Komipharm International Co., Ltd. | Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis |
| US20090246291A1 (en) * | 2008-03-27 | 2009-10-01 | Angelika Burger | Method and compositions for treatment of cancer |
| CN102060722B (zh) * | 2009-05-01 | 2014-06-11 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种含砷化合物及其制备方法和用途 |
| EP2359812A1 (en) | 2010-01-18 | 2011-08-24 | Cephalon France | Oral lyophilised compositions |
| CN105435228B (zh) * | 2014-08-14 | 2020-08-07 | 中国科学院上海营养与健康研究所 | 三氧化二砷的抗肿瘤新用途及抗肿瘤制剂 |
| AU2016212703B2 (en) * | 2015-01-29 | 2017-12-07 | Eupharma Pty Ltd | Compositions containing arsenic and their use in methods of treatment |
| JP6928768B2 (ja) | 2015-02-01 | 2021-09-01 | サイロス・ファーマシューティカルズ・インコーポレイテッドＳｙｒｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物 |
| MX2019006107A (es) * | 2016-12-01 | 2019-08-21 | Eupharma Pty Ltd | Composiciones de arsenico. |
-
2017
- 2017-08-02 MX MX2019006107A patent/MX2019006107A/es unknown
- 2017-08-02 PL PL17876251.4T patent/PL3548044T3/pl unknown
- 2017-08-02 TW TW106126050A patent/TWI808060B/zh active
- 2017-08-02 ES ES17876251T patent/ES2964979T3/es active Active
- 2017-08-02 EP EP17876251.4A patent/EP3548044B1/en active Active
- 2017-08-02 CA CA3041357A patent/CA3041357A1/en active Pending
- 2017-08-02 JP JP2019524985A patent/JP7080230B2/ja active Active
- 2017-08-02 CN CN201780069613.2A patent/CN109952105A/zh active Pending
- 2017-08-02 AU AU2017368444A patent/AU2017368444B9/en active Active
- 2017-08-02 SG SG11201903064SA patent/SG11201903064SA/en unknown
- 2017-08-02 DK DK17876251.4T patent/DK3548044T3/da active
- 2017-08-02 NZ NZ752214A patent/NZ752214A/en unknown
- 2017-08-02 US US16/465,693 patent/US11241453B2/en active Active
- 2017-08-02 IL IL265986A patent/IL265986B/en unknown
- 2017-08-02 WO PCT/AU2017/050807 patent/WO2018098519A1/en unknown
- 2017-08-02 KR KR1020197013881A patent/KR102487884B1/ko active IP Right Grant
- 2017-08-02 BR BR112019007498A patent/BR112019007498A2/pt active Search and Examination
- 2017-08-02 PE PE2019000939A patent/PE20191544A1/es unknown
-
2019
- 2019-04-05 ZA ZA2019/02156A patent/ZA201902156B/en unknown
- 2019-05-27 CL CL2019001422A patent/CL2019001422A1/es unknown
- 2019-05-29 SA SA519401885A patent/SA519401885B1/ar unknown
-
2022
- 2022-02-25 JP JP2022028046A patent/JP7419415B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| NZ752214A (en) | 2022-11-25 |
| ZA201902156B (en) | 2021-01-27 |
| KR102487884B1 (ko) | 2023-01-11 |
| AU2017368444B9 (en) | 2020-07-02 |
| CN109952105A (zh) | 2019-06-28 |
| KR20190089865A (ko) | 2019-07-31 |
| SA519401885B1 (ar) | 2023-12-24 |
| AU2017368444A1 (en) | 2019-04-18 |
| SG11201903064SA (en) | 2019-05-30 |
| PE20191544A1 (es) | 2019-10-24 |
| TW201821087A (zh) | 2018-06-16 |
| PL3548044T3 (pl) | 2024-03-04 |
| BR112019007498A2 (pt) | 2019-07-02 |
| JP7419415B2 (ja) | 2024-01-22 |
| TWI808060B (zh) | 2023-07-11 |
| ES2964979T3 (es) | 2024-04-10 |
| WO2018098519A1 (en) | 2018-06-07 |
| EP3548044A1 (en) | 2019-10-09 |
| JP7080230B2 (ja) | 2022-06-03 |
| JP2020500845A (ja) | 2020-01-16 |
| US20200016196A1 (en) | 2020-01-16 |
| AU2017368444B2 (en) | 2020-04-30 |
| EP3548044A4 (en) | 2020-07-22 |
| IL265986A (en) | 2019-06-30 |
| DK3548044T3 (en) | 2023-12-11 |
| CL2019001422A1 (es) | 2019-08-02 |
| CA3041357A1 (en) | 2018-06-07 |
| EP3548044B1 (en) | 2023-09-20 |
| IL265986B (en) | 2022-09-01 |
| US11241453B2 (en) | 2022-02-08 |
| JP2022069485A (ja) | 2022-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519401885B1 (ar) | تركيبات زرنيخ | |
| MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
| TN2017000452A1 (en) | Compositions of obeticholic acid and methods of use | |
| PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| MX2018001721A (es) | 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer. | |
| NZ733174A (en) | Quinazoline derivatives used to treat hiv | |
| PH12018500987A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| PH12018502497A1 (en) | Adenosine derivatives for use in the treatment of cancer | |
| MX2016011897A (es) | Composiciones de compuestos selenoorganicos y metodos de uso de los mismos. | |
| EA033446B1 (ru) | Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта | |
| EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
| MX361642B (es) | Composiciones antisépticas catiónicas. | |
| UY35735A (es) | Trifluorometilpirimidinonas disustituidas y su uso | |
| PH12018501709A1 (en) | Naphthridinedione derivatives | |
| EA032654B9 (ru) | [1,2,4]ТРИАЗОЛО[4,3-b]ПИРИДАЗИНЫ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
| WO2016040814A3 (en) | Disulfide polymers and methods of use | |
| MX2018007112A (es) | Composicion de peroximonosulfato de disolucion rapida. | |
| UA116913C2 (uk) | Спосіб отримання ксантогумолу | |
| WO2015160470A3 (en) | Nadph production by the 10-formyl-thf pathway, and its use in the diagnosis and treatment of disease | |
| MX2015012720A (es) | Sales basicas de adicion de nitroxolina y usos de las mismas. | |
| NZ757526A (en) | Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction | |
| MX2017009659A (es) | Composiciones que contienen arsenico y su uso en metodos de tratamiento. | |
| WO2016057660A8 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |